Completion of Canadian Patent for Mitochondrial Disease Curatives

We are pleased to announce that we have acquired a Canadian patent for our developed mitochondrial disease therapeutic substance, ML1 polyamide. With this, patents for ML1 polyamide in all countries filed by our company have been approved.
For details, please refer to public information from related organizations in the future. Thank you very much.